Cerebrolysin [215.2 mg/mL, 10mL ampule for IV infusion] for the treatment of post-ischemic stroke
Pre-Cycle 1 | DrugsHTA Council Recommendation (as of 13 April 2023)
The HTA Council does not recommend government financing of cerebrolysin 215.2mg/mL , 10 mL ampule for IV infusion, in combination with rehabilitation, for the treatment of adults post-ischemic stroke, thus its non-inclusion in the Philippine National Formulary. (See below for more details)
Relevant Information
- Status: With Final HTA Council Recommendation
- Topic Assignment: Internal Assessment
- Policy Question: Should cerebrolysin (215.2mg/mL , 10 mL ampule for IV infusion), be included in the Philippine National Formulary (PNF) for the treatment of post-ischemic stroke across different levels of severity?
- Secretary of Health Decision: Noted as of 25 April 2023
Evidence and Relevant Documents
- HTAC Final Recommendation
- Secretary of Health Decision – OIC- Secretary noted the HTA Council Recommendation on cerebrolysin through a letter dated 25 April 2023.
- Evidence Summary